Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 09, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Looking Into Dyne Therapeutics's Recent Short Interest ↗

October 22, 2024

Via Benzinga

Peering Into Dyne Therapeutics's Recent Short Interest ↗

September 30, 2024

Via Benzinga

January 08, 2025

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Dyne Therapeutics to Present at Upcoming Investor Conferences

November 07, 2024

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

October 09, 2024

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

September 23, 2024

Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm

September 20, 2024

From Bragar Eagel & Squire

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

September 16, 2024

From Bronstein, Gewirtz & Grossman, LLC

DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm

September 10, 2024

From Bragar Eagel & Squire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)

September 09, 2024

From Kirby McInerney LLP

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

September 08, 2024

From Bronstein, Gewirtz & Grossman, LLC

DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

September 04, 2024

From The Schall Law Firm

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗

September 03, 2024

Via Benzinga

September 03, 2024

Via Benzinga

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗

September 03, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...

Via Benzinga

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building ↗

September 03, 2024

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.

Via Investor's Business Daily

Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗

September 03, 2024

Via Benzinga

Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates ↗

September 03, 2024

Via Benzinga

Topics Stocks

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 03, 2024

Via Benzinga

Dyne Therapeutics Announces Key Leadership Appointments

September 03, 2024

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

September 03, 2024

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

Find out the significance of the

Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity? ↗

August 21, 2024

Via Talk Markets

Topics Stocks

Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? ↗

August 13, 2024

A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to...

Via Benzinga

Topics Economy

DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 ↗

August 12, 2024

DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 12, 2024